BioSpace News Archive

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the Company has completed the submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for casimersen (SRP-4045).

In the rapidly evolving field of sports nutrition, a few key factors can make or break a company’s success. Up and coming sports nutrition brands have some fierce competition in the supplement market, and many brands simply find ways to recreate the same products, but Armourgenix®

Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage developer of antibodies for cancer immune-therapy, today reported its financial results for the first quarter ended March 31, 2020 . “We are exploring strategic opportunities for our anti-CTLA-4 antibody, which shows strong comparative results in pre-clinical cancer tr

BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”) a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced that its subsidiary, BioStem Life Sciences, has added California and Maryland to its list of tissue bank licenses issued by the individual state’s Department of Health. “This is a significant achievement in the ongoing growth of BioStem

Abbott (NYSE: ABT) today announced new data from the company’s LightLab Initiative that showed optical coherence tomography (OCT) imaging significantly changes how physicians decide to treat a vessel compared to traditional angiography by providing physicians improved visualization within a patient’s blood vessels.

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, announced upcoming changes to its Board of Directors.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today announced the pricing of its underwritten public offering of 4,216,868 shares of common stock at a public offering price of $8.30 per share

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Kevin Hrusovsky, Chairman and Chief Executive Officer of Quanterix and Founder of the non-profit Powering Precision Health (PPH), will participate in the MassBio: Possible Talk series on June 26, 2020 at 10 a.m. EDT

AnHeart Therapeutics, Co., Ltd . (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, today announced that its Phase 1 taletrectinib data has been accepted for publication in Clinical Cancer Research , a prestigious oncology journal of the American Association for Cancer Research. The paper is entitled “US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK i

Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly